Bioresorbable vascular scaffolds: between promises and reality.
作者信息
Montone Rocco A, Brown Adam J, Niccoli Giampaolo
机构信息
Rocco A. Montone: Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy and Interventional Cardiology, ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
出版信息
Oncotarget. 2017 Sep 1;8(41):69202-69203. doi: 10.18632/oncotarget.20630. eCollection 2017 Sep 19.
Abstract
摘要
相似文献
1
Bioresorbable vascular scaffolds: between promises and reality.生物可吸收血管支架：在承诺与现实之间
Oncotarget. 2017 Sep 1;8(41):69202-69203. doi: 10.18632/oncotarget.20630. eCollection 2017 Sep 19.
2
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架的比较：随机对照试验的荟萃分析。
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
3
The Current Literature on Bioabsorbable Stents: a Review.生物可吸收支架的最新文献综述。
Curr Atheroscler Rep. 2019 Nov 25;21(12):54. doi: 10.1007/s11883-019-0816-4.
4
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.生物可吸收支架与金属支架在常规 PCI 中的应用比较。
N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.
5
Perioperative Management of Dual-Antiplatelet Therapy in Patients With New-Generation Drug-Eluting Metallic Stents and Bioresorbable Vascular Scaffolds Undergoing Elective Noncardiac Surgery.接受择期非心脏手术的新一代药物洗脱金属支架和生物可吸收血管支架患者双重抗血小板治疗的围手术期管理
J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1857-1864. doi: 10.1053/j.jvca.2017.04.046. Epub 2017 Apr 26.
6
Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling.生物可吸收血管支架：生物降解、药物递送与血管重塑。
Pharmacol Res. 2016 May;107:163-171. doi: 10.1016/j.phrs.2016.03.020. Epub 2016 Mar 18.
7
Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives.双重抗血小板治疗、药物洗脱支架和生物可吸收血管支架：进化视角
Catheter Cardiovasc Interv. 2016 Apr;87(5):909-19. doi: 10.1002/ccd.26099. Epub 2015 Aug 10.
8
Bioresorbable vascular scaffold for very late stent thrombosis resulting from ruptured neoatherosclerosis.生物可吸收血管支架用于治疗由新生动脉粥样硬化破裂导致的极晚期支架内血栓形成。
Rev Port Cardiol. 2015 Dec;34(12):779.e1-4. doi: 10.1016/j.repc.2015.05.008. Epub 2015 Nov 27.
9
"The Unpredictable ABSORB" - Very Late Stent Thrombosis of Bioresorbable Vascular Scaffold.“不可预测的ABSORB”——生物可吸收血管支架的极晚期支架内血栓形成
Heart Views. 2019 Apr-Jun;20(2):65-69. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_18_19.
10
Very Late Bioresorbable Vascular Scaffold Thrombosis: Smoke or Fire?极晚期生物可吸收血管支架血栓形成：是烟雾还是火灾？
JACC Cardiovasc Interv. 2017 Jan 9;10(1):38-41. doi: 10.1016/j.jcin.2016.11.038.
本文引用的文献
1
Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.比较金属和聚合型可吸收生物支架的急性血栓形成：Magmaris 与 Absorb 在猪动静脉分流模型中的对比。
Circ Cardiovasc Interv. 2017 Aug;10(8). doi: 10.1161/CIRCINTERVENTIONS.116.004762.
2
Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架置入后不良事件的时间趋势：随机对照试验的荟萃分析。
Circulation. 2017 May 30;135(22):2145-2154. doi: 10.1161/CIRCULATIONAHA.117.028479.
3
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.生物可吸收支架与金属支架在常规 PCI 中的应用比较。
N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.
4
Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease.冠状动脉生物可吸收血管支架在冠状动脉疾病治疗中的应用。
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.116.003978.
5
Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.生物可吸收冠状动脉支架血栓形成：多中心临床特征、机制和预测因素的综合分析。
J Am Coll Cardiol. 2016 Mar 1;67(8):921-931. doi: 10.1016/j.jacc.2015.12.019.
6
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.依维莫司洗脱生物可吸收支架治疗冠状动脉疾病。
N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.
7
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.生物可吸收依维莫司洗脱支架与金属依维莫司洗脱支架治疗初发原生冠状动脉病变所致缺血性心脏病的比较（ABSORB II）：一项随机对照临床试验的临床和操作次要终点 1 年中期分析。
Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.
Zotero 插件